Dr. Bilinsky most recently served as Chief Operating Officer at AmpliPhi Biosciences, a biotechnology company developing a new therapeutic class of targeted therapies for patients with life-threatening bacterial infections that do not respond to antibiotics. Previously, Dr. Bilinsky was General Manager, Immuno-Oncology and Senior Vice President, Special Operations and Research Operations at Ignyta Inc., a biotechnology company focused on precision medicine in oncology that was acquired by Roche. Prior to Ignyta, he was Senior Vice President, Corporate Development at Vical Inc., Vice President, Business Development and Special Operations at Halozyme Therapeutics, and Chief Executive Officer at Androclus Therapeutics. Dr. Bilinsky was previously a principal in the healthcare practice of Boston Consulting Group, where he advised companies in the biotechnology and pharmaceutical industries on business strategy, operational performance and mergers and acquisitions. Dr. Bilinsky received his B.S. degree in physics from the Moscow Institute of Physics and Technology and his Ph.D. degree in physics from the Massachusetts Institute of Technology.